{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:44:16Z","timestamp":1793105056327,"version":"4.5.0"},"posted":{"date-parts":[[2025,9,8]]},"group-title":"Immunology","reference-count":51,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,9,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Repetitive display of the major repeats of the\n                  <jats:italic>Plasmodium falciparum<\/jats:italic>\n                  circumsporozoite protein (PfCSP) is the basis for two WHO-recommended vaccines: RTS,S\/AS01 and R21\/Matrix-M. Recently, however, the CIS43 monoclonal antibody that preferentially targets the junctional region of PfCSP has been shown to be highly protective in humans, highlighting its junctional epitope as a key vaccine target. Here, we develop a vaccine based on the tandem repeats of the junctional epitope displayed on a self-assembling nanoparticle, and compare this CIS43-based junctional vaccine alone or in combination with the benchmark R21 vaccine, using both B cell analysis and monoclonal antibody isolation to define targeting of the immune response. Comparable reduction in liver burden was observed following vaccination with junctional and R21 vaccines at a dose of 1 \u03bcg. At a dose of 0.25 \u03bcg, a modest reduction of malaria-liver burden with the junctional vaccine was observed compared to R21. Further, combining junctional and R21 vaccines induced modestly enhanced protection compared to either vaccine alone. While the R21 vaccine elicited antibodies primarily against the major repeats, the junctional vaccine elicited antibodies against both junctional and major repeat regions.\n                  <jats:italic>In vivo<\/jats:italic>\n                  -B cell analysis and isolation of monoclonal antibodies confirmed differences in vaccine-induced antibody specificities. Altogether, these data suggest the nanoparticle-formatted tandem-repeated CIS43-junctional vaccine to be a promising approach to broaden immunity against malaria, either as a standalone intervention or in combination with R21.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>HIGHLIGHTS<\/jats:title>\n                  <jats:list list-type=\"bullet\">\n                    <jats:list-item>\n                      <jats:p>Developed a self-assembling nanoparticle-displayed junctional vaccine of PfCSP based on tandem repeats of the epitope preferentially targeted by the highly protective CIS43 antibody<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>The CIS43-based junctional vaccine at low doses significantly reduced liver burden following malaria challenge in mice<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>Following either low or high doses of the junctional vaccine in na\u00efve mice, adoptively transferred B cells expressing the CIS43 inferred germline sequence yielded a high frequency of germinal center and ASC responses<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>The CIS43-based junctional vaccine elicits antibodies against junctional and major repeat regions whereas the R21 vaccine elicits responses primarily against the major repeat region<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>At low dose, the CIS43-based junctional vaccine given together with the R21 vaccine showed modestly improved control of liver burden compared to either vaccine alone<\/jats:p>\n                    <\/jats:list-item>\n                  <\/jats:list>\n                <\/jats:sec>","DOI":"10.1101\/2025.09.05.665822","type":"posted-content","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:10:16Z","timestamp":1757322616000},"source":"Crossref","is-referenced-by-count":2,"title":["Protective immunity against malaria by a nanoparticle CIS43-based junctional vaccine alone or in combination with R21"],"prefix":"10.64898","author":[{"given":"Prabhanshu","family":"Tripathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja-Hyun","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lais Da","family":"Silva Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariah","family":"Lofgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Ting","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kerscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Pui","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Ransier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaroslav","family":"Tsybovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie R.","family":"Weldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny C.","family":"Douek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore C.","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Facundo D.","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza H.","family":"Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Seder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3560-232X","authenticated-orcid":false,"given":"Peter D.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3935-4637","authenticated-orcid":false,"given":"Tongqing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025091101050706000_2025.09.05.665822v1.1","unstructured":"World malaria report 2024. (2024)."},{"key":"2025091101050706000_2025.09.05.665822v1.2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.157.6.1947"},{"key":"2025091101050706000_2025.09.05.665822v1.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.6204383"},{"key":"2025091101050706000_2025.09.05.665822v1.4","unstructured":"WHO review of malaria vaccine clinical development. (2025)."},{"key":"2025091101050706000_2025.09.05.665822v1.5","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.6.1576"},{"key":"2025091101050706000_2025.09.05.665822v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/srep46621"},{"key":"2025091101050706000_2025.09.05.665822v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"2025091101050706000_2025.09.05.665822v1.8","unstructured":"Life-saving malaria vaccines reach children in 17 endemic countries in 2024."},{"key":"2025091101050706000_2025.09.05.665822v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02511-4"},{"key":"2025091101050706000_2025.09.05.665822v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00442-X"},{"key":"2025091101050706000_2025.09.05.665822v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00943-0"},{"key":"2025091101050706000_2025.09.05.665822v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00239-X"},{"key":"2025091101050706000_2025.09.05.665822v1.13","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0117-2"},{"key":"2025091101050706000_2025.09.05.665822v1.14","doi-asserted-by":"crossref","unstructured":"Minsoko, P.A. et al. Efficacy and Safety of the RTS,S\/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites. Plos Medicine 11(2014).","DOI":"10.1371\/journal.pmed.1001685"},{"key":"2025091101050706000_2025.09.05.665822v1.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206966"},{"key":"2025091101050706000_2025.09.05.665822v1.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312775"},{"key":"2025091101050706000_2025.09.05.665822v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2015.11.001"},{"key":"2025091101050706000_2025.09.05.665822v1.18","doi-asserted-by":"crossref","unstructured":"Morales-Hernandez, S. , Ugidos-Damboriena, N. & Lopez-Sagaseta, J . Self-Assembling Protein Nanoparticles in the Design of Vaccines: 2022 Update. Vaccines (Basel) 10(2022).","DOI":"10.3390\/vaccines10091447"},{"key":"2025091101050706000_2025.09.05.665822v1.19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf3309"},{"key":"2025091101050706000_2025.09.05.665822v1.20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41541-024-00959-0","article-title":"Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine","volume":"9","year":"2024","journal-title":"NPJ Vaccines"},{"key":"2025091101050706000_2025.09.05.665822v1.21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade4790"},{"key":"2025091101050706000_2025.09.05.665822v1.22","doi-asserted-by":"crossref","first-page":"110143","DOI":"10.1016\/j.celrep.2021.110143","article-title":"SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity","volume":"37","year":"2021","journal-title":"Cell Rep"},{"key":"2025091101050706000_2025.09.05.665822v1.23","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1016\/S2666-5247(23)00410-X","article-title":"SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial","volume":"5","year":"2024","journal-title":"Lancet Microbe"},{"key":"2025091101050706000_2025.09.05.665822v1.24","doi-asserted-by":"crossref","unstructured":"Swanson, K.A. et al. A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain. Sci Immunol 5(2020).","DOI":"10.1126\/sciimmunol.aba6466"},{"key":"2025091101050706000_2025.09.05.665822v1.25","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/fvl-2020-0174","article-title":"Nanoparticle vaccines against respiratory syncytial virus","volume":"15","year":"2020","journal-title":"Future Virol"},{"key":"2025091101050706000_2025.09.05.665822v1.26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41541-020-00274-4","article-title":"An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein","volume":"6","year":"2021","journal-title":"NPJ Vaccines"},{"key":"2025091101050706000_2025.09.05.665822v1.27","doi-asserted-by":"crossref","unstructured":"Francica, J.R. et al. Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria. Vaccines 9(2021).","DOI":"10.3390\/vaccines9030272"},{"key":"2025091101050706000_2025.09.05.665822v1.28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-022-00457-1","article-title":"A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model","volume":"7","year":"2022","journal-title":"NPJ Vaccines"},{"key":"2025091101050706000_2025.09.05.665822v1.29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41541-023-00653-7","article-title":"Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model","volume":"8","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2025091101050706000_2025.09.05.665822v1.30","doi-asserted-by":"crossref","unstructured":"Sun, Z.W. et al. An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene. Emerging Microbes & Infections 5(2016).","DOI":"10.1038\/emi.2016.86"},{"key":"2025091101050706000_2025.09.05.665822v1.31","doi-asserted-by":"crossref","first-page":"10722","DOI":"10.1021\/acsnano.1c04078","article-title":"Antigen-Presenting, Self-Assembled Protein Nanobarrels as an Adjuvant-Free Vaccine Platform against Influenza Virus","volume":"15","year":"2021","journal-title":"Acs Nano"},{"key":"2025091101050706000_2025.09.05.665822v1.32","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4512"},{"key":"2025091101050706000_2025.09.05.665822v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.10.017"},{"key":"2025091101050706000_2025.09.05.665822v1.34","doi-asserted-by":"crossref","unstructured":"Reveiz, M. et al. In Silico Improvement of Highly Protective Anti-Malarial Antibodies. bioRxiv, 2022.04.08.487687 (2022).","DOI":"10.1101\/2022.04.08.487687"},{"key":"2025091101050706000_2025.09.05.665822v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.im-muni.2020.08.014"},{"key":"2025091101050706000_2025.09.05.665822v1.36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1715812114"},{"key":"2025091101050706000_2025.09.05.665822v1.37","doi-asserted-by":"publisher","DOI":"10.4103\/0976-0105.177703"},{"key":"2025091101050706000_2025.09.05.665822v1.38","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1988.tb03104.x"},{"key":"2025091101050706000_2025.09.05.665822v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/334258a0"},{"key":"2025091101050706000_2025.09.05.665822v1.40","doi-asserted-by":"publisher","DOI":"10.1038\/336778a0"},{"key":"2025091101050706000_2025.09.05.665822v1.41","doi-asserted-by":"publisher","DOI":"10.1007\/BF02788751"},{"key":"2025091101050706000_2025.09.05.665822v1.42","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit282"},{"key":"2025091101050706000_2025.09.05.665822v1.43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1803457115"},{"key":"2025091101050706000_2025.09.05.665822v1.44","doi-asserted-by":"crossref","unstructured":"McDaniel, J.R. et al. Repertoire, function, and structure of serological antibodies induced by the R21\/Matrix-M malaria vaccine. J Exp Med 222(2025).","DOI":"10.1084\/jem.20241908"},{"key":"2025091101050706000_2025.09.05.665822v1.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0881-9"},{"key":"2025091101050706000_2025.09.05.665822v1.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02659-z"},{"key":"2025091101050706000_2025.09.05.665822v1.47","doi-asserted-by":"crossref","first-page":"113330","DOI":"10.1016\/j.celrep.2023.113330","article-title":"Molecular determinants of cross-reactivity and potency by VH3-33 antibodies against the Plasmodium falciparum circumsporozoite protein","volume":"42","year":"2023","journal-title":"Cell Rep"},{"key":"2025091101050706000_2025.09.05.665822v1.48","doi-asserted-by":"crossref","first-page":"10792","DOI":"10.1038\/s41598-021-90290-8","article-title":"Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice","volume":"11","year":"2021","journal-title":"Sci Rep"},{"key":"2025091101050706000_2025.09.05.665822v1.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.10.032"},{"key":"2025091101050706000_2025.09.05.665822v1.50","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn8934"},{"key":"2025091101050706000_2025.09.05.665822v1.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35456-2"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.09.05.665822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:13:36Z","timestamp":1782278016000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.09.05.665822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1101\/2025.09.05.665822","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41541-026-01455-3","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,9,8]]},"subtype":"preprint"}}